Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 5-6, 2010, Pages 351-357

  Gerrits, Mireille ^a   De Greef, Rik ^a   Peeters, Pierre ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Asenapine; Buccal; Pharmacokinetics; Sublingual; Supralingual

Indexed keywords

ASENAPINE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; EVENING DOSAGE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH CAVITY; NORMAL HUMAN; ORAL PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOMNOLENCE; ADOLESCENT; ADULT; BUCCAL DRUG ADMINISTRATION; MIDDLE AGED; SUBLINGUAL DRUG ADMINISTRATION; THERAPEUTIC EQUIVALENCE;

ADMINISTRATION, BUCCAL; ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CROSS-OVER STUDIES; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 77955681479     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.718     Document Type: Article

References (11)

1. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255-264.
2. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006; 8: 232-241.
3. El-Mallakh RS. Medication adherence and the use of long-acting antipsychotics in bipolar disorder. J Psychiatr Pract 2007; 13: 79-85.
4. Dogterom P, Timmer C, de Greef R, Spaans E, de Vries D, Peeters PAM. A phase I study to investigate the safety, tolerability, and pharmacokinetics of single and multiple doses of sublingually administered asenapine in healthy male volunteers. Clin Pharmacol Ther 2009; 85(suppl 1): S86.
5. Hulskotte EGJ, Spaans E, Timmer CJ, et al.Effects of water intake and smoking on absorption of sublingually administered asenapine. Clin Pharmacol Ther 2009; 85(suppl 1): S86.
6. Shyu WC, Mayol RF, Pfeffer M, Pittman KA, Gammans RE, Barbhaiya RH. Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharm Drug Dispos 1993; 14: 371-379.
7. Kuhlman Jr JJ, Lalani S, Magluilo Jr J, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996; 20: 369-378.
8. Kokki H, Rasanen I, Lasalmi M, et al. Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. Clin Pharmacokinet 2006; 45: 745-754.
9. Darwish M, Kirby M, Jiang JG, Tracewell W, Robertson P, Jr. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. Clin Drug Investig 2008; 28: 1-7.
10. Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 2009; 86: 84-91.
11. de Greef R, Friberg LE, Chapel S, et al. Modeling and simulation to integrate efficacy and safety data following full development: a case study in schizophrenia and bipolar disorder. Presented at: Population Approach Group in Europe; 18-20 June 2008; Marseille, France (abstract available at: http://www.page-meeting.org/default.asp?abstract=1274).